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INTRODUCTION
R
aman spectroscopy can provide details of the chemi-
cal composition of tissues. It is a nondestructive
technique requiring no sample preparation, making
it an attractive method for in vivo and in vitro char-
acterization of biological tissues. A Raman spectrum
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ABSTRACT:
Raman spectroscopy shows potential in differentiating
tumors from normal tissue. We used Raman spectroscopy
with near-infrared light excitation to study normal breast
tissue and tumors from 11 mice injected with a cancer cell
line. Spectra were collected from 17 tumors, 18 samples of
adjacent breast tissue and lymph nodes, and 17 tissue
samples from the contralateral breast and its adjacent
lymph nodes. Discriminant function analysis was used for
classification with principal component analysis scores as
input data. Tissues were examined by light microscopy
following formalin fixation and hematoxylin and eosin
staining. Discriminant function analysis and histology
agreed on the diagnosis of all contralateral normal, tumor,
and mastitis samples, except one tumor which was found to
be more similar to normal tissue. Normal tissue adjacent to
each tumor was examined as a separate data group called
tumor bed. Scattered morphologically suspicious atypical
cells not definite for tumor were present in the tumor bed
samples. Classification of tumor bed tissue showed that
some tumor bed tissues are diagnostically different from
normal, tumor, and mastitis tissue. This may reflect
malignant molecular alterations prior to morphologic
changes, as expected in preneoplastic processes. Raman
spectroscopy not only distinguishes tumor from normal
breast tissue, but also detects early neoplastic changes prior
to definite morphologic alteration. # 2007 Wiley
Periodicals, Inc. Biopolymers 89: 235–241, 2008.
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provides a molecular fingerprint, and the intensity of the
Raman peaks is directly proportional to the concentration of
the molecules. Traditional disease classification including
cancer is based on the morphologic appearance of tissues
(histology). These morphologic changes are accompanied by
changes in chemical composition. Thus, Raman spectroscopy
is likely to be a useful technique.1–11
The objectives of this study were to evaluate the sensitivity
and specificity of Raman spectroscopy in differentiating
between cancer and normal breast tissue in a mouse model.
MATERIALS AND METHODS
Animal Experiments
All experiments received prior approval from the Animal Investiga-
tion Committee at Wayne State University. A highly malignant
BALB/c tumor cell line (4T1) was used in this study.12 Eleven
BALB/c (Taconic Farms, Germantown, NY) female mice (6- to 8-
weeks old) were injected subcutaneously at the nipple of the 5th
mammary gland on one side, with a suspension of 1 3 105 4T1 tu-
mor cells. All mice developed tumor nodules at the injection site.
The mice were humanely killed 10–14 days following injection.
Tumors and adjacent breast tissue were removed for analysis. Adja-
cent breast tissue often included lymph nodes. The contralateral
mammary gland and its adjacent lymph nodes were also removed.
Specimens were evaluated histologically and with near-infrared
(NIR) Raman spectroscopy. When lymph nodes were found histo-
logically, they were also analyzed with Raman spectroscopy. Samples
were divided in two. One was submitted for histology and one for
Raman spectroscopy. After Raman spectroscopy, the samples used
for Raman analysis were also submitted for histology.
Histology
Samples were fixed in 10% (v/v) neutral buffered zinc formalin so-
lution (Richard Allan Scientific) and processed overnight. Following
embedding, 5 lm sections were cut and stained with hematoxylin–
eosin.
NIR Raman Spectroscopic Measurements
Raman spectra were recorded using a Renishaw Raman microscope
(RM1000, equipped with a thermoelectric cooled 578 3 385 pixel
CCD), using a 203 objective in the 600–1800 cm21 spectral range.
A 785 nm laser line was used to excite the Raman spectra with
50 mW of power at the sample. The spectra were collected in line-
mode with a measured length and width of laser excitation of
130 lm 3 25 lm. Typical cell size is on the order of 20 lm, and the
line-mode was used to acquire spectra from a range of cells. This
should be the preferred method in the operating room, as the sur-
geon would be unable to sample each cell individually because of
limited cell selectivity and time constraints.
All Raman measurements used a 10 s exposure time, and three
exposures were averaged to obtain a better signal-to-noise ratio. The
spectral resolution was 4 cm21. To assess intrasample variability,
multiple measurements (n  12) were made on each sample at dif-
ferent regions. This was accomplished by placing samples on an xyz
motorized, computer-controlled sample stage. Points to be analyzed
were chosen randomly from the microscopic image of the tissue
available on the Renishaw spectrometer.
Raman Spectrum Processing
Raman spectra of tissues contain a combination of Raman scatter-
ing, intrinsic tissue fluorescence, and noise. Preprocessing steps
include cosmic-ray removal, noise subtraction, and removal of tis-
sue fluorescence and normalization of the data. Each spectrum was
represented as a set of 601 variables at 2 cm21 intervals. A median
filter was applied to the raw data to eliminate cosmic rays or spikes.
Then noise was filtered using wavelets.13 The background fluores-
cence was subtracted from the denoised spectra using a modified
cubic spline algorithm. Unlike other cubic spline fits, this algorithm
requires no a priori knowledge of the spectra.14 The subtracted spec-
trum was normalized so that the minimum and maximum values of
the spectrum were 0 and 1, respectively. Matlab version 6.5 was used
to preprocess the data.
Tissue Classification Methods and Data Analysis
Principal component (PC) analysis was first used to reduce the
dimensionality of the dataset to simplify the data analysis. Discrimi-
nant function analysis (DFA) was used for tissue classification. It is
a supervised classification method that builds classification rules for
a number of prespecified categories.15 It correlates the weighting
coefficients (scores) of the PCs calculated for each Raman spectrum
with diagnostic categories. A leave-one-out classification algorithm
was used to ensure the validity of the analysis.
RESULTS
Histological Evaluations
From the contralateral side, we collected normal breast tis-
sue which often contained lymph nodes (Figure 1a). From
the injected side, we collected tumor (Figure 1b), and adja-
cent breast tissue with lymph nodes (Figure 1c). We will
refer to adjacent breast tissue with its accompanying lymph
nodes as the tumor bed. Histology confirmed poorly differ-
entiated adenocarcinoma in all 17 tumor samples. No defi-
nite tumor cells were found in any of the normal mammary
tissue (tumor bed or contralateral), and no definite tumor
cells were found in any of the lymph nodes from either side.
The tumor bed samples showed reactive stromal cells, some
inflammatory cells, and a few scattered large atypical cells
with large hyperchromatic nuclei and a moderate amount of
cytoplasm; however, they displayed no definite tumor aggre-
gates (Figure 1c). In practice, atypical cells are hard to clas-
sify and are often overlooked. Two mice showed mastitis (fat
necrosis and chronic inflammation) in their mammary
gland tissue, one from tumor bed and two from contralat-
eral breast (Figure 1d).
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Raman Spectroscopy
We collected 650 spectra. Because of the small size of the
mammary glands and lymph nodes, we were not able to sep-
arate these tissues grossly. Some of the breast tissue samples
contained tiny lymph nodes, and some of the lymph node
samples contained breast tissue. For this reason, we analyzed
the spectra in four diagnostic categories: (a) contralateral
breast with lymph node, (b) tumor, (c) tumor bed, and (d)
mastitis. Figure 2 shows the corresponding normalized mean
Raman spectra. Note the visual differences in the peak
heights of the four spectra.
Data Analysis
Mean Spectra Analysis. We first conducted an analysis of
normal, tumor, and mastitis tissues to confirm the diagnostic
ability of DFA. Raman and histology agreed in all cases, except
one tumor sample which was more characteristic of normal
tissue (Table I). This may be because the sample was largely
made up of normal cells, with fewer tumor components.
We then analyzed the data using all four tissues—that is
including tumor bed (Figure 2). These were also analyzed using
DFA, with PC scores as the input using leave-one-out analysis.
We used the mean spectra of each tissue to analyze the data, and
then reanalyzed the data using individual spectra (Table II).
Using mean spectra, 14 of 17 normal samples were correctly
identified, 16 of 17 tumor samples were correctly identified,
and all mastitis samples were correctly identified. Raman accu-
racy decreased slightly when including tumor bed, presumably
because some tumor bed samples had characteristics of tumor
while some had characteristics of normal tissue. Of 18 tumor
bed samples, 9 were similar to the contralateral breast (normal),
and 6 had specific changes separating them from normal tissue,
2 showed changes consistent with mastitis, and only 1 sample
showed changes consistent with the other tumor samples. All
mastitis samples were correctly identified.
Individual Spectra Analysis. Individual spectra also con-
firmed the ability of Raman to differentiate normal, tumor,
and mastitis tissues. All normal and mastitis spectra were cor-
rectly identified, and 91% of tumor spectra were correctly
identified. The other 9% were classified as normal and masti-
tis, consistent with normal pockets trapped within the tumor.
Using individual spectra, 79% of normal tissue samples
were correctly identified, while the other 21% were identified
as tumor bed. Within the tumor group, 0.4% were identified
as normal, 10% were called tumor bed, 2.2% were called
mastitis, and 87.3% were called tumor. All mastitis samples
were correctly identified. Within the tumor bed, 49.2% of
samples were identified as normal, 5.6% were identified as
FIGURE 1 Histology images of typical (a) normal mammary gland with small benign lymph
node seen in the left lower field, (b) tumor, (c) tumor bed (arrows point to atypical cells), and (d)
mastitis.
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FIGURE 2 Mean Raman spectra of (a) normal mammary gland tissue with lymph nodes, (b) tu-
mor, (c) tumor bed, and (d) mastitis. The gray region designates the 95% confidence interval for
each peak.
Table I Leave-One-Out DFA Classification Results Using Three Data Groups
Tissue Type
Mean Spectra Analysis (n) Casewise Analysis (n)
Samples Normal Tumor Mastitis Samples Normal Tumor Mastitis
Normal 17 17 189 189
Tumor 17 1 16 229 15 209 5
Mastitis 3 3 37 37
The number in each column represents the number of cases per group as classified by the diagnostic method.
Table II Leave-One-Out Results of DFA for Tumor Bed Analysis
Tissue Type
Mean Spectra Analysis (n) Casewise Analysis (n)
Samples Normal Tumor Mastitis Tumor Bed Samples Normal Tumor Mastitis Tumor Bed
Normal 17 14 3 189 150 39
Tumor 17 16 1 229 1 200 5 23
Mastitis 3 3 37 37
Tumor bed 18 9 1 2 6 195 96 11 10 78
The number in each column represents the number of cases per group as classified by the diagnostic method.
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tumor, 5.1% were identified as mastitis, and 40% were accu-
rately called tumor bed.
DISCUSSION
Several literature sources identify specific molecular struc-
tures with specific Raman peaks. The relevant peak assign-
ments for our data are noted in Table III. The Raman spec-
trum of normal mammary gland and associated lymph nodes
(Figure 2a) is dominated by contribution from lipids. The
peaks at 1004, 868, and 762 cm21 reflect the protein-rich
composition of the tissue.
The Raman spectra of mammary gland tumors (Figure 2b)
reflect increased protein and reduced lipid compared to
normal mammary gland tissue. This is demonstrated by (i)
decreased intensity of the 1746 cm21 peak due to C¼O
stretch of phospholipids, (ii) the decreased intensity of the
1440 cm21, and (iii) new or more intense protein peaks
around 1576, 1446, 1338, 1318, 1258, 1174, 1004, 936, 854,
830, 642, and 622 cm21.
The spectral profile of tumor bed (Figure 2c) produced
the same peaks as normal mammary gland tissue, with some
slight changes in the peak intensities.
Table III Tentative Peak Assignments
Normal Mam. Gland Tumor Mastitis Tumor Bed Assignment
622 C C twisting mode of phenylalanine16–18
642 C C twist of tyrosine16,18
666 664 T ,G and m(C S) of cysteine (DNA/RNA)17,18
724 718 718 720 CN (membrane phospholipid head)/nucleotide peak symmetric
choline stretch, phospholipids, (H3C)N1 stretch band16,19–21
754 752 Symmetric breathing of tryptophan18
762 758 Symmetric ring breathing of tryptophan, ms(O PO)16,17,19,22
784 782 U,C,T ring breathing, DNA17
830 Out-of-plane ring breathing tyrosine/m(O PO), DNA16
854 852 852 Ring breathing of tyrosine and m(C C) hydroxyproline ring
specific to collagen16,17,19
868 870 Proline18
876 m(C C), hydroxyproline11
936 m(C C) protein backbone a-helix (proline/glycogen),
collagen16,17,19,20,23,24
968 970 d(¼CH) wagging3
1004 1004 1002 1004 mS symmetric ring breathing mode, phenylalanine
16,17,19,24
1032 d (CH), phenylalanine16
1046 CO stretching of carbohydrates17
1084 1088 1084 1084 CN stretching of proteins and lipids, m(C C) and m(CO) of
phospholipids17,18,25
1120 1126 1126 m(C C)of lipids from trans segments and m(CN)of proteins24
1174 d(CH), tyrosine16
1258 Amide III, b-sheet/adenine and cytosine16,17,20
1264 1264 1264 d(¼CH)of lipids11,16,17,20,24
1302 1302 (CH2) twist, phospholipids and collagen
17,25
1318 Guanine, CH3CH2 wagging nucleic acids, CH3CH2 wagging
collagen11,17
1338 Amide III, hydrated a-helix d(NH) and m(CN), desmosine/
isodesmosine(elastin) (A and G of DNA/RNA)16,17,19,26
1344 A and G of DNA/RNA and CH deformation of proteins27
1364 1362 1366 Guaninine, TRP (protein), lipids18
1440 1446 1438 1440 d (CH2) d as (CH3) in proteins (around 1449) and lipids (around
1438)19,20,24,28
1576 1574 Tryptophan, Nucleic acids( guanine, adenine) TRP protein16,20,28
1656 1658 1658 1656 (Amide I, a-helix) , t(C¼O) of proteins collagen, elastin and
m(C¼C) of lipids(around 1654 cm21)17,18,26
1746 1746 m(C¼O) of phospholipids11,19,29
m, stretching mode; ms, symmetric stretch; mas, asymmetric stretch; d, bending mode.
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Mastitis is characterized by destruction of mature adipose
tissue with sheets of inflammatory cells and foamy macro-
phages. Raman spectra of mastitis (Figure 2d) lacked the
phospholipid peak at 1747 cm21 and showed superimposed
peaks in the 1200–1500 cm21 region, resulting in a notice-
ably broad spectral feature.
Other studies have also shown the ability of Raman spectros-
copy to accurately classify diseased tissue in brain,16,17 skin,18–24
cervix,25–27 breast,1,2,9,10,28–33 and other organs.8,11,34–44 Our
data is confirmatory, and, in addition, demonstrates changes in
the tumor bed, which probably represent the detection of
chemical signs of preneoplastic changes.
Not every Raman spectra correctly classifies every tissue
sample. The reason that some spectra from a sample are differ-
ent is that all samples contain a variety of tissues, such as
blood vessels, residual normal organ tissue, and fat.25,26 For
example, Figure 3 shows the Raman spectra of six different
points on the same tumor sample. There are clear differences
in the spectral (and therefore chemical) compositions between
points b, c, d, e, and a and f, which may reflect two trapped
normal components within a tumor sample. Even tumor sam-
ples can be expected to contain normal blood vessels and fat.
Thus, it would not be a rare event for the Raman microscope
to interrogate normal tissue within the tumor. For this reason
we take at least 12 spectra from each sample and eliminate the
obviously aberrant spectra. We then decide on the diagnosis
using the average of all spectra obtained from that sample.
Our results firmly support the ability of Raman spectra, when
appropriately averaged, preprocessed, and analyzed, to reach
the same diagnostic conclusions as histology.
While these results are promising, they may misconstrue
the actual diagnostic ability of Raman spectroscopy. All spec-
tra were collected under controlled conditions with little inter-
sample variability, under the supervision of trained patholo-
gists. In a less-controlled in vivo study, the diagnostic ability
may be reduced because of increased variability in collection
method and less premeasurement knowledge of the sample.
In clinical practice, malignant tumors are usually excised
with a significant amount of surrounding normal tissue to
guarantee complete removal of atypical and preneoplastic
cells. Raman spectroscopy indicates that surrounding normal
tissue is not the same as the contralateral normal breast.
Most of the ‘‘errors’’ that were made were in classification of
the tumor bed. Some tumor bed tissues were distinctly differ-
ent from normal, tumor, and mastitis tissues. This may
reflect malignant molecular alterations prior to morphologic
changes, as would be expected in preneoplastic processes.
Before Raman can be translated to in vivo use, many bar-
riers must be overcome. A new system should be designed,
which can be integrated into an existing surgical tool, such as
an endoscope or needle biopsy system. To meet this chal-
lenge, a fiber-optic probe must be designed, which can be
inserted into the needle or endoscope. Ideally, the fiber
would reduce the collection time to fractions of a second
while also reducing fluorescence. Accompanying software
must preprocess and classify the data in near real-time to
give an immediate diagnosis in the operating room.
Our study demonstrates that tissues have characteristic
Raman spectral features that differentiate pathologic changes
like mastitis and cancer from normal breast tissue in a mouse
model. It also suggests that Raman spectroscopy can detect
molecular preneoplastic changes prior to histologic altera-
tions. This is a rapid technique and requires no prior prepa-
ration of tissue. Tissue can be examined in vitro or in vivo in
seconds, and if a library of spectral profiles of various tissues
and pathologic conditions is created, comparison and inter-
pretation can be performed in real-time. It may offer a
quicker, less-subjective method to detect cancer as a supple-
ment to current histological methods. With the rapid devel-
opment and improvement of optic and computer technol-
ogy, fiber-optic Raman probes may be used by clinicians to
detect malignancy and by surgeons to guide surgical exci-
sions in the not very distant future.
The authors thank Children’s Hospital of Michigan, Detroit, MI, for
partially funding this effort.
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